docetaxel anhydrous has been researched along with halofuginone in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (halofuginone) | Trials (halofuginone) | Recent Studies (post-2010) (halofuginone) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 326 | 16 | 136 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genin, O; Iluz, M; Kawada, N; Leon, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y; Yoshizato, K | 1 |
1 other study(ies) available for docetaxel anhydrous and halofuginone
| Article | Year |
|---|---|
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Synergism; Fibroblasts; Humans; Male; Mice; Mice, Nude; Muscles; Myoblasts; Piperidines; Prostatic Neoplasms; Quinazolinones; Taxoids; Tumor Cells, Cultured; Wilms Tumor | 2007 |